Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Toripalimab + axitinib in patients with metastatic mucosal melanoma

Sunandana Chandra, MD, MS, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, discusses a Phase Ib combination study of toripalimab, a humanized IgG4 mAb against PD-1 with axitinib in patients with mucosal melanoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).